Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of “Buy” from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received a consensus rating of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have covered the stock in the last year is $6.63.

Several research firms have recently issued reports on TSHA. Chardan Capital restated a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, February 27th.

Taysha Gene Therapies Trading Down 3.2 %

Shares of NASDAQ TSHA opened at $1.22 on Friday. Taysha Gene Therapies has a 1-year low of $1.17 and a 1-year high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The business’s 50 day moving average is $1.63 and its two-hundred day moving average is $1.88. The stock has a market capitalization of $250.10 million, a P/E ratio of 1.94 and a beta of 0.96.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.01. The company had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. As a group, research analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current year.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of hedge funds have recently added to or reduced their stakes in the stock. Octagon Capital Advisors LP boosted its holdings in shares of Taysha Gene Therapies by 128.6% in the fourth quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company’s stock valued at $18,078,000 after purchasing an additional 5,877,778 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in Taysha Gene Therapies during the 4th quarter valued at $8,650,000. Bank of America Corp DE lifted its holdings in shares of Taysha Gene Therapies by 1,178.9% in the 4th quarter. Bank of America Corp DE now owns 1,710,303 shares of the company’s stock worth $2,959,000 after buying an additional 1,576,568 shares during the period. Norges Bank bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth $2,528,000. Finally, Avoro Capital Advisors LLC increased its stake in shares of Taysha Gene Therapies by 7.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company’s stock valued at $34,600,000 after buying an additional 1,349,999 shares during the period. 77.70% of the stock is currently owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.